Literature DB >> 6361806

Targeting potential of antibody conjugates.

D C Edwards.   

Abstract

Although the use of conjugates of enzymes has been considered, their use has not been very actively pursued. Much more interest has focused on the possibilities offered by the use of toxins, their subunits or of ribosome inhibitors. Conjugates of holotoxin which were very active and specific in vitro have been prepared. High in vivo activity and some specificity together with reduced whole body toxicity has been described. When A chain subunits or ribosome inhibiting proteins are used, the results are more mixed. Some very active and specific conjugates are known but others have relatively low activity. The reasons for this may be associated with the particular antigen to which the antibody component is directed, the nature of the A chain or inhibitor and the type and physiological state of the target cell. Application to man seems likely in the first instance to involve the removal of undesirable cells from bone marrow transplants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6361806     DOI: 10.1016/0163-7258(83)90029-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  8 in total

Review 1.  Monoclonal antibodies as magic bullets.

Authors:  F M Brodsky
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

2.  Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide.

Authors:  D E Kerr; P D Senter; W V Burnett; D L Hirschberg; I Hellström; K E Hellström
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Selective killing of T lymphocytes by phototoxic liposomes.

Authors:  S Yemul; C Berger; A Estabrook; S Suarez; R Edelson; H Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

4.  Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Authors:  J M Trang; A F LoBuglio; R H Wheeler; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

5.  Membrane-bound alkaline phosphatase gene induces antitumor effect by G2/M arrest in etoposide phosphate-treated cancer cells.

Authors:  Kye Young Kim; Young Joo Cho; Geoung A Jeon; Pan Dong Ryu; Jin Nam Myeong
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy.

Authors:  M D Vincent; T J Powles; R C Coombes; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Selective destruction of nerve growth factor receptor-bearing cells in vitro using a hybrid toxin composed of ricin A chain and a monoclonal antibody against the nerve growth factor receptor.

Authors:  P S DiStefano; J B Schweitzer; M Taniuchi; E M Johnson
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

Review 8.  Animal viruses of economic importance: genetic variation, persistence, and prospects for their control.

Authors:  J B Hudson
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.